Tamoxifen: profile and news

Pak1 expression increases tamoxifen resistance in breast cancer ...  16 May 2006
...protein that activates estrogen receptors in breast cancer may play a role in resistance to therapeutic effects of anti-estrogen tamoxifen treatment, according ... - EurekAlert (press release),

EntreMed hoping for success with Panzem/Avastin combo  16 May 2006
...inhibition. Panzem has shown preclinical activity against taxanes, DNA synthesis interfering agents and tamoxifen-resistant models. ... - Pharmaceutical Business Review

New York Times Reporter Examines Recent Study Comparing Raloxifene ...  May 10, 2006
...initial results from a National Cancer Institute-sponsored study showing that the drug raloxifene is as good as another drug, tamoxifen, in preventing breast ... - Kaiser network.org,

Tamoxifen Use Associated With Smaller Optic Cup Size: Presented at ...  May 5, 2006
FORT LAUDERDALE, FL -- May 4, 2006 -- Patients taking tamoxifen in the treatment of breast cancer appear to have smaller optic-cup sizes due to subclinical ... - DG News

New Breast Cancer Drug Safer Than Tamoxifen  Apr 17, 2006
MONDAY, April 17 (HealthDay News) -- The osteoporosis drug raloxifene equals tamoxifen in reducing breast cancer risk in high-risk postmenopausal women, but ... - Forbes

Raloxifene Reduces Breast Cancer Risk As Well As Tamoxifen  Apr 17, 2006
A study called STAR, Study of Tamoxifen and Raloxifene has shown, according to initial results, that Raloxifene is as effective as Tomoxifen in the prevention ... - Medical News Today,

Cousin of tamoxifen prevents breast cancer  Apr 18, 2006
A newer drug prevents breast cancer in older, high-risk women just as well as today's standby tamoxifen -- but with fewer side effects, the National Cancer ... - Seattle Post Intelligencer

Lilly`s Evista beats tamoxifen  Apr 17, 2006
RUTH trial, welcomed positive results from the STAR trial released Monday that suggest the osteoporosis drug may be a superior choice to tamoxifen for reducing ... - Monsters and Critics.com,

Evista as good as tamoxifen for breast cancer: study  Apr 17, 2006
WASHINGTON (Reuters) - The osteoporosis drug Evista works as well as tamoxifen in reducing the risk of breast cancer in high-risk older women, with fewer ... - Reuters.uk,

Drug equals tamoxifen in preventing breast cancer: Study  Apr 17, 2006
...to reduce the incidence of invasive breast cancer in high-risk, post-menopausal women as effectively as the current gold-standard drug tamoxifen — but with ... - Toronto Star,

Drug equals tamoxifen in preventing breast cancer: Study  Apr 17, 2006
...drug has been found to reduce the incidence of invasive breast cancer in high-risk, post-menopausal women as effectively as Tamoxifen, the medication ... - Toronto Star,

Osteoporosis drug as effective as tamoxifen: study  Apr 17, 2006
The results of an international breast cancer study shows that the drug raloxifene is as effective as tamoxifen in the prevention of the invasive disease. ... - CTV.ca,

STAR Study: Raloxifene is as effective as Tamoxifen in reducing ...  Apr 20, 2006
By NSABP, The Study of Tamoxifen and Raloxifene, or STAR, is a clinical trial designed see how the drug raloxifene compares with the drug tamoxifen in reducing ... - RxPG NEWS,

Study of Tamoxifen and Raloxifene (STAR) Results: Osteoporosis ...  Apr 17, 2006
SEATTLE — April 17, 2006 — Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and ... - Hutchinson Center A Life of Science,

Osteoporosis drug Raloxifene shown to be as effective as Tamoxifen ...  Apr 17, 2006
Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in ... - News-Medical.net,

Raloxifene trumps tamoxifen in safety trials for breast cancer  Apr 18, 2006
Initial results of a clinical trial suggest that the osteoporosis drug raloxifene (trade name Evista) is as effective as tamoxifen (trade name Nolvadex) in ... - Food Consumer,

Raloxifene as Good as Tamoxifen to Prevent Breast Cancer  Apr 17, 2006
The bone drug raloxifene (Evista) is just as good as tamoxifen in preventing invasive breast cancer in high-risk women, federal health officials announced today ... - ACS News Center,

Raloxifene or tamoxifen: Which is the right drug for you?  Apr 19, 2006
Yet few have opted to take tamoxifen, the only drug now approved for breast cancer risk reduction, because it raises the risk of uterine cancer and potentially ... - AZ Central.com,

Osteoporosis drug equals tamoxifen in preventing breast cancer  Apr 17, 2006
One of the largest breast cancer prevention trials ever conducted has found that an osteoporosis drug was as good as tamoxifen at preventing breast cancer ... - Pittsburgh Post Gazette,

Raloxifene as effective as Tamoxifen in preventing invasive breast ...  Apr 18, 2006
Preliminary results of the STAR ( Study of Tamoxifen and Raloxifene ) trial showed that the drug Raloxifene ( Evista ), currently used to prevent and treat ... - Xagena.it,

Study shows osteoporosis drug as good as Tamoxifen  Apr 18, 2006
BETHESDA – April 17, 2006 – Initial results of as study comparing tamoxifen and a newer drug, raloxifene, shows that raloxifene is at least as effective as ... - Cancerfacts.com,

Osteoporosis Drug As Effective as Tamoxifen in Reducing Breast ...  Apr 17, 2006
Preliminary results from a large study of postmenopausal women finds that the osteoporosis drug raloxifene is as effective as tamoxifen in reducing the risk of ... - Cancerpage.com,

Evista may be a better option than Tamoxifen for reducing breast ...  Apr 17, 2006
According to drug company Lilly it's osteoporosis drug Evista is as effective as Tamoxifen in reducing the risk of breast cancer in high-risk women. ... - News-Medical.net,

Drug has fewer side effects, is as effective as Tamoxifen, study ...  Apr 17, 2006
Raloxifene prevents breast cancer in high-risk women just as well as today's standby Tamoxifen but with fewer side effects, the National Cancer Institute ... - Munster Times,

Raloxifene Better Than Tamoxifen For Breast Cancer  Apr 18, 2006
The osteoporosis drug Evista is better than Tamoxifen in preventing breast cancer in high risk post-menopausal women, new research has suggested. ... - MedIndia,

Comment: Should Women Switch From Tamoxifen to Raloxifene (Evista) ...  Apr 18, 2006
Rather, what the NIH study says is that Tamoxifen reduces the risk for invasive breast cancer by about 50% (in hard numbers, it's a reduction of only about 1.2 ... - Food Consumer,

Evista Equivalent to Tamoxifen for Breast Cancer Patients  Apr 18, 2006
In results of 19,000 woman trial show that Eli Lilly and Co's Evista, known generically as raloxifene, is less likely than tamoxifen to cause certain types of ... - Half Life Source

Eli Lilly Releases Statement On Results Of Study Of Tamoxifen And ...  Apr 17, 2006
...(LLY | charts | news | PowerRating) issued the following statement related to the release of high-level results of the Study of Tamoxifen and Raloxifene, STAR ... - Trading Markets,

New Breast Cancer Drug, Safer Than Tamoxifen  Apr 17, 2006
Researchers with the National Cancer Institute say a new drug prevents breast cancer in postmenopausal women just as well as tamoxifen – but with fewer side ... - ktla 5,

Pre-Operative Arimidex® Provides Greater Responses than Tamoxifen ...  May 3, 2006
...journal Cancer, treatment with Arimidex® (anastrazole) prior to surgery provides greater anticancer responses than treatment with tamoxifen (Nolvadex®) in ... - Cancer Consultants (press release),

Pre-Operative Arimidex® Provides Greater Responses than Tamoxifen ...  May 4, 2006
Study have reported that treatment with Arimidex® (anastrazole) prior to surgery results in equivalent or greater responses than tamoxifen (Nolvadex®) in ... - Cancer Consultants (press release),

Tamoxifen vs. Raloxifene  Apr 19, 2006
20,000 woman across the country recently participated in a Star clinical trial, including some from the Mid Ohio Valley. Camden ... - WTAP-TV,

Osteoporosis Drug As Effective As Tamoxifen In Preventing Invasive ...  Apr 20, 2006
Initial results of the Study of Tamoxifen and Raloxifene (STAR), in which Yale Cancer Center participated, show that the drug raloxifene, currently used to ... - Medical News Today (press release),

Bone Thinning Drug Raloxifene As Effective As Tamoxifen In ...  Apr 20, 2006
The bone thinning drug raloxifene is as effective as the breast cancer prevention drug tamoxifen in reducing breast cancer risk for postmenopausal women ... - Medical News Today (press release),

Osteoporosis drug raloxifene shown to be as effective as tamoxifen ...  Apr 18, 2006
Initial results of the Study of Tamoxifen and Raloxifene (STAR) released: Osteoporosis drug raloxifene shown to be as effective as tamoxifen in preventing ... - PressZoom (press release),

Evista® as Effective as Tamoxifen in Preventing Breast Cancer ...  Apr 18, 2006
Institute, the rate at which Evista® (raloxifene) reduces the risk of developing breast cancer is equal to that of Nolvadex® (tamoxifen) in postmenopausal ... - Cancer Consultants (press release),

Raloxifene Shows Advantages Over Tamoxifen in Breast Cancer ...  Apr 18, 2006
NEW YORK (Reuters Health) Apr 17 - Initial results from the Study of Tamoxifen and Raloxifene (STAR) trial show that the anti-osteoporosis drug raloxifene ... - Medscape (subscription)

Lilly's Evista rivals tamoxifen in breast cancer  Apr 18, 2006
...of the large-scale STAR clinical trial reveal that Eli Lilly's osteoporosis drug Evista is as effective as the widely-used anti-oestrogen tamoxifen in reducing ... - Pharma Times (subscription),

Study: Evista safer than tamoxifen in preventing breast cancer  Apr 18, 2006
WASHINGTON - A newer drug prevents breast cancer in older, high-risk women just as well as today’s standby tamoxifen — but with fewer side effects, the ... - Canton Repository (subscription),

Sorting Out Pills to Reduce Breast Cancer Risk  May 10, 2006
By DENISE GRADY. THE ISSUE: The drug tamoxifen has been shown to reduce breast cancer risk, but few women take it. ... But is it really any better than tamoxifen? ... - New York Times,

Women needlessly having breast cancer surgery: doctor  May 15, 2006
Dr Morrow believes a drug currently used for osteoporosis may supersede Tamoxifen, a drug used in preventing relapses of breast cancer. ... - ABC Online,

Lilly Calls Tamoxifen/Raloxifene Study Important Milestone  Apr 17, 2006
Eli Lilly & Co. (LLY) said results from Tamoxifen and Raloxifene trials conducted by researchers with the National Surgical Adjuvant Breast and Bowel Project ... - Therapeutics Daily (subscription) (press release),

Evista as good as tamoxifen for breast cancer: study  Apr 18, 2006
In April 17 WASHINGTON story headlined "UPDATE 2-Evista as good as tamoxifen for breast cancer-study," please read in fourth paragraph ... ... - Reuters.uk,

Evista is as effective as Tamoxifen for Breast Cancer  Apr 18, 2006
As per the Study of Tamoxifen and Raloxifene-STAR Trial which released positive results on Monday that suggest the osteoporosis drug may be a superior choice ... - 24x7updates,

Evista as good as tamoxifen for breast cancer: study  Apr 17, 2006
WASHINGTON - The osteoporosis drug Evista works as well as tamoxifen in reducing the risk of breast cancer in high-risk older women, with fewer dangerous side ... - Olberlin,

New drug safer than tamoxifen?  Apr 18, 2006
WASHINGTON - A newer drug prevents breast cancer in older, high-risk women just as well as today's standby tamoxifen - but with fewer side effects, the ... - Philadelphia Daily News,

Safer alternative for breast cancer drug tamoxifen  Apr 17, 2006
A newer drug prevents breast cancer in older, high-risk women just as well as today's standby tamoxifen - but with fewer side effects, the National Cancer ... - Macon Telegraph,

Is new breast cancer pill better?  May 11, 2006
A second drug, raloxifene, left, was announced to be just as good as tamoxifen at preventing breast cancer -- with fewer side effects. See full image. ... - DetNews.com,

When NOLVADEX is used in combination with coumarin-type anticoagulants, a significant increase in anticoagulant effect may occur. Where such coadministration exists, careful monitoring of the patientís prothrombin time is recommended.

In the NSABP P-1 trial, women who required coumarin-type anticoagulants for any reason were ineligible for participation in the trial.

There is an increased risk of thromboembolic events occurring when cytotoxic agents are used in combination with NOLVADEX.

Tamoxifen reduced letrozole plasma concentrations by 37%. The effect of tamoxifen on metabolism and excretion of other antineoplastic drugs, such as cyclophosphamide and other drugs that require mixed function oxidases for activation, is not known. Tamoxifen and N-desmethyl tamoxifen plasma concentrations have been shown to be reduced when coadministered with rifampin or aminoglutethimide. Induction of CYP3A4-mediated metabolism is considered to be the mechanism by which these reductions occur; other CYP3A4 inducing agents have not been studied to confirm this effect.

One patient receiving NOLVADEX with concomitant phenobarbital exhibited a steady state serum level of tamoxifen lower than that observed for other patients (ie, 26 ng/mL vs. mean value of 122 ng/mL). However, the clinical significance of this finding is not known. Rifampin induced the metabolism of tamoxifen and significantly reduced the plasma concentrations of tamoxifen in 10 patients. Aminoglutethimide reduces tamoxifen and N desmethyl tamoxifen plasma concentrations. Medroxyprogesterone reduces plasma concentrations of N-desmethyl, but not tamoxifen.

Concomitant bromocriptine therapy has been shown to elevate serum tamoxifen and N-desmethyl tamoxifen.

Drug/Laboratory Testing Interactions:

During postmarketing surveillance, T4 elevations were reported for a few postmenopausal patients which may be explained by increases in thyroid-binding globulin. These elevations were not accompanied by clinical hyperthyroidism.

Variations in the karyopyknotic index on vaginal smears and various degrees of estrogen effect on Pap smears have been infrequently seen in postmenopausal patients given NOLVADEX.

In the postmarketing experience with NOLVADEX, infrequent cases of hyperlipidemias have been reported. Periodic monitoring of plasma triglycerides and cholesterol may be indicated in patients with pre-existing hyperlipidemias .

 

Chemical IUPAC Name
[5-(2-amino-6-oxo-3,9-dihydropurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-[(3,4-dihydroxy-6-methyl-5-oxo-tetrahydropyran-2-yl)oxy-hydroxy-phosphoryl]oxy-phosphinicacid

Chemical Formula
C16H23N5O15P2

Half Life
5-7 days

Drug Type
Approved Drug

# Accession No
APRD00123

CAS Registry Number
10540-29-1